IDEAYA Biosciences (IDYA) Competitors $28.15 -1.31 (-4.45%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends IDYA vs. CPRX, XENE, CUE, OSMT, SYRS, ROIV, LEGN, VKTX, LNTH, and ASNDShould you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Catalyst Pharmaceuticals (CPRX), Xenon Pharmaceuticals (XENE), Cue Biopharma (CUE), Osmotica Pharmaceuticals (OSMT), Syros Pharmaceuticals (SYRS), Roivant Sciences (ROIV), Legend Biotech (LEGN), Viking Therapeutics (VKTX), Lantheus (LNTH), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector. IDEAYA Biosciences vs. Catalyst Pharmaceuticals Xenon Pharmaceuticals Cue Biopharma Osmotica Pharmaceuticals Syros Pharmaceuticals Roivant Sciences Legend Biotech Viking Therapeutics Lantheus Ascendis Pharma A/S IDEAYA Biosciences (NASDAQ:IDYA) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and community ranking. Is IDYA or CPRX more profitable? Catalyst Pharmaceuticals has a net margin of 15.69% compared to IDEAYA Biosciences' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 27.77% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -20.52% -19.73% Catalyst Pharmaceuticals 15.69%27.77%23.68% Do analysts rate IDYA or CPRX? IDEAYA Biosciences currently has a consensus target price of $55.45, indicating a potential upside of 95.54%. Catalyst Pharmaceuticals has a consensus target price of $29.50, indicating a potential upside of 35.38%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe IDEAYA Biosciences is more favorable than Catalyst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07Catalyst Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of IDYA or CPRX? 98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 3.5% of IDEAYA Biosciences shares are held by insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to IDYA or CPRX? In the previous week, IDEAYA Biosciences had 13 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 19 mentions for IDEAYA Biosciences and 6 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 0.70 beat IDEAYA Biosciences' score of 0.31 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 3 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Catalyst Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, IDYA or CPRX? Catalyst Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$11.96M180.34-$112.96M-$2.01-14.18Catalyst Pharmaceuticals$434.48M5.93$71.41M$0.5440.39 Which has more volatility and risk, IDYA or CPRX? IDEAYA Biosciences has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Does the MarketBeat Community favor IDYA or CPRX? Catalyst Pharmaceuticals received 355 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. Likewise, 74.58% of users gave Catalyst Pharmaceuticals an outperform vote while only 71.43% of users gave IDEAYA Biosciences an outperform vote. CompanyUnderperformOutperformIDEAYA BiosciencesOutperform Votes13571.43% Underperform Votes5428.57% Catalyst PharmaceuticalsOutperform Votes49074.58% Underperform Votes16725.42% SummaryCatalyst Pharmaceuticals beats IDEAYA Biosciences on 11 of the 19 factors compared between the two stocks. Ad Porter & CompanyThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. Click here now to grab your seat now. Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDYA vs. The Competition Export to ExcelMetricIDEAYA BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.16B$7.14B$5.37B$8.40BDividend YieldN/A8.77%5.21%4.20%P/E Ratio-13.0116.47140.7317.73Price / Sales180.34254.681,437.0778.19Price / CashN/A50.1638.9433.56Price / Book2.965.684.744.59Net Income-$112.96M$151.16M$115.38M$225.45M7 Day Performance-2.40%-1.43%-0.60%-0.22%1 Month Performance-10.04%6.29%3.92%1.93%1 Year Performance4.90%40.64%39.36%33.41% IDEAYA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDYAIDEAYA Biosciences4.3471 of 5 stars$28.15-4.4%$55.45+97.0%+14.4%$2.13B$11.96M-12.8580Upcoming EarningsAnalyst ForecastShort Interest ↓CPRXCatalyst Pharmaceuticals4.7745 of 5 stars$21.81+1.2%$29.50+35.3%+76.7%$2.58B$434.48M40.39167Upcoming EarningsXENEXenon Pharmaceuticals3.429 of 5 stars$41.30-1.4%$57.45+39.1%+33.0%$3.12B$9.43M-15.07251Options VolumePositive NewsCUECue Biopharma4.6209 of 5 stars$1.54-12.0%$5.00+224.7%-8.9%$74.91M$8.30M-1.5960Positive NewsOSMTOsmotica PharmaceuticalsN/AN/AN/AN/A$69.47M$177.88M-0.70302SYRSSyros Pharmaceuticals4.5145 of 5 stars$2.50-0.4%$5.00+100.0%+0.4%$66.82M$4.15M-0.58120ROIVRoivant Sciences2.9572 of 5 stars$11.64-1.2%$17.39+49.4%+39.4%$8.61B$158.30M2.09860LEGNLegend Biotech1.9903 of 5 stars$45.16+2.0%$82.08+81.7%-32.6%$8.23B$455.99M-57.901,800Analyst ForecastVKTXViking Therapeutics4.1451 of 5 stars$73.37+2.3%$108.60+48.0%+649.0%$8.09BN/A-78.8920Insider SellingAnalyst RevisionLNTHLantheus4.3315 of 5 stars$108.91-0.4%$126.00+15.7%+77.6%$7.55B$1.44B17.85834Upcoming EarningsNews CoveragePositive NewsASNDAscendis Pharma A/S3.0356 of 5 stars$124.03+1.0%$195.92+58.0%+40.5%$7.22B$317.63M-13.32640Upcoming EarningsPositive News Related Companies and Tools Related Companies Catalyst Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives Cue Biopharma Alternatives Osmotica Pharmaceuticals Alternatives Syros Pharmaceuticals Alternatives Roivant Sciences Alternatives Legend Biotech Alternatives Viking Therapeutics Alternatives Lantheus Alternatives Ascendis Pharma A/S Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IDYA) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IDYA Stock Alerts